Part of the Pemphigus & Autoimmune Blistering Disease Knowledge Library
She did not arrive asking for the blisters to go. She arrived because every attempt to lower the steroid produced a flare worse than the last.
| Age at first consultation | 68 |
|---|---|
| Duration before EliteAyurveda | 4 months on high-dose steroids |
| Disease pattern at presentation | Biopsy-confirmed; taper-dependent, flaring on every reduction |
| Presenting picture | Disturbed sleep, raised blood sugar and facial puffiness — steroid-driven, not disease-driven |
| Prior treatment | High-dose systemic corticosteroids |
| Dominant drivers identified | Immune · Gut · Metabolic |
A woman of sixty-eight with biopsy-confirmed bullous pemphigoid, four months into high-dose corticosteroids. The blisters were largely controlled — but she had not come about the blisters. She had come because every attempt to bring the steroid dose down produced a flare worse than the one before it.
That is a specific and exhausting trap. The drug was holding the disease, and the disease had made itself dependent on the drug. Meanwhile the steroids were writing their own picture over the top: disturbed sleep, raised blood sugar, facial puffiness. None of that was the disease. All of it was the treatment.
A taper-and-flare cycle is easy to read as a disease that simply needs the steroid — and sometimes, for a time, it does. But a flare on every reduction is also what you see when the inflammatory load underneath has never actually come down. The dose is holding a lid on a pot that is still boiling.
Nothing about the dermatology care was wrong. High-dose steroids are the right tool to get tense, widespread blistering under control quickly. The problem is that they were the only tool in play, and they cannot address why the immune disturbance keeps regenerating — which is why the lid could never safely come off.
The plan was built after assessing digestion, the immune pattern, the extent of skin involvement, and the medication history, with the emphasis on gradual internal correction introduced step by step — not sudden change.
That follows the EPOH phase sequence: lowering the inflammatory load first, then internal healing and gut repair, then clearance, with home-applied external care for the skin and a low-intensity maintenance set afterwards.
The same boundary applies here as in every steroid case, and it is worth stating plainly. We do not taper steroids, and we do not advise dose changes. Prednisolone, azathioprine, mycophenolate, rituximab — every one of those decisions belongs to the prescribing doctor. What internal work offers a taper-dependent patient is not a faster taper. It is a quieter disease beneath the one the dermatologist is tapering, so that the next reduction is attempted on better ground.
On the skin: blistering stayed controlled, and — for the first time in months — reductions in the steroid dose stopped triggering a worse flare. The record describes the taper, made by the dermatologist, proceeding without the rebound that had defined every earlier attempt.
Off the skin, the steroid side-effects that had come to dominate her days began to ease as the dose came down: sleep improved, blood sugar settled, the facial puffiness receded. Appetite and digestion steadied. What changed most was not any single blister but the direction of the whole picture — for months it had only tightened, and now it was loosening.
The person this describes did not have uncontrolled disease. She had controlled disease she could not get out from under — and that is its own kind of stuck, one a success rate measured only in blister counts would completely miss.
It remains supportive care alongside a dermatologist, never instead of one, and a single record establishes no rate and proves no cause: pemphigoid fluctuates by nature and she remained under dermatology care throughout. The honest claim is the modest one — when the disease underneath is quieter, the taper a dermatologist has been fighting for becomes a taper they can finish.
Medical disclaimer. This is one patient's documented course of treatment. Individual response varies with disease duration, degree of involvement and remaining biological repair capacity — not every patient reaches the same outcome. Nothing here is a substitute for personalised medical advice, and no medication should be started, stopped or altered without consulting your treating physician.
